Response to ‘Comment on ‘‘Adjuvant Trastuzumab Therapy for Early HER2-Positive Breast Cancer in Iran: A Cost-Effectiveness and Scenario Analysis for an Optimal Treatment Strategy”’

2018-02-09

Key Points:
It is necessary to include future non-breast cancer costs in cost-effectiveness analyses.

Inclusion of future non-breast cancer costs does not change our conclusions about the optimal treatment strategy in Iran.

Additional Metadata
Persistent URL	doi.org/10.1007/s40273-018-0620-y, hdl.handle.net/1765/104709
Journal	PharmacoEconomics
Organisation	Institute for Medical Technology Assessment (iMTA)
Citation APA Style AAA Style APA Style Cell Style Chicago Style Harvard Style IEEE Style MLA Style Nature Style Vancouver Style American-Institute-of-Physics Style Council-of-Science-Editors Style BibTex Format Endnote Format RIS Format CSL Format DOIs only Format	Ansaripour, A., Uyl-de Groot, C., & Redekop, K. (2018). Response to ‘Comment on ‘‘Adjuvant Trastuzumab Therapy for Early HER2-Positive Breast Cancer in Iran: A Cost-Effectiveness and Scenario Analysis for an Optimal Treatment Strategy”’. PharmacoEconomics, 1–2. doi:10.1007/s40273-018-0620-y

See Also
article Adjuvant Trastuzumab Therapy for Early HER2-Positive Breast Cancer in Iran: A Cost-Effectiveness and Scenario Analysis for an Optimal Treatment Strategy A. Ansaripour (Amir), C.A. Uyl-de Groot (Carin) and W.K. Redekop (Ken)

Publication